Screener
Regeneron Pharmaceuticals REGN Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| (In millions) / As of June 30, 2026 | Amortized / Cost Basis | Unrealized / Gains | Unrealized / Losses | Fair / Value |
|---|---|---|---|---|
| Certificates of deposit | 304.4 | — | (0.3) | 304.1 |
| Asset-backed securities | 193.2 | 0.2 | (0.3) | 193.1 |
| Sovereign bonds | 78.5 | 0.1 | (0.3) | 78.3 |
| $15,220.7 | $21.0 | $(52.5) | $15,189.2 | |
| As of December 31, 2025 | ||||
| Corporate bonds | $10,141.0 | $80.9 | $(2.4) | $10,219.5 |
| U.S. government and government agency obligations | 4,352.2 | 15.2 | (0.1) | 4,367.3 |
| Commercial paper | 540.8 | 0.3 | — | 541.1 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's unrealized losses on investments (before tax)?
- Regeneron Pharmaceuticals (REGN) reported unrealized losses on investments (before tax) of $52.5M in Q2 2026.
Ask your AI about Regeneron Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude